Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers. The team, led by Richard G. Pestell, Director of the KCC and the Chair of the Department of Cancer Biology at Thomas Jefferson University, report their preclinical findings from a blinded, retrospective analysis of over 350 patients and mouse study in the journal of Cancer Research. Read more here.
Study mentioned: Ju X, et al. Novel Oncogene Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures. Cancer Res. 2012 Nov 30. [Epub ahead of print] PMID: 23204233
No comments:
Post a Comment